LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
Narikazu Boku, M.-H. Ryu, D-Y. Oh, Sang Cheul Oh, Hyun Cheol Chung, Kyung-Woo Lee, Takeshi Omori, Kohei Shitara, S. Sakuramoto, Ick‐Joong Chung, Kensei Yamaguchi, Katsuhiko Kato, Sun Jin Sym, Shigenori Kadowaki, Kunihiro Tsuji, Jin‐Shing Chen, L-Y. Bai, L-T. Chen, Y-K. Kang
Topics & Concepts
MedicineCapecitabineClinical endpointInternal medicineNivolumabOxaliplatinChemotherapyInterim analysisChemotherapy regimenGastroenterologyCancerPhases of clinical researchProgression-free survivalPlaceboOncologySurgeryRandomized controlled trialColorectal cancerImmunotherapyPathologyAlternative medicineGastric Cancer Management and OutcomesEsophageal Cancer Research and TreatmentCancer Immunotherapy and Biomarkers